Evidence map›Paper›PMID 25800393›Full record

ReviewNature reviews. Urology2015

Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer.

Ashish M Kamat, Thomas W Flaig, H Barton Grossman, Badrinath Konety, Donald Lamm, Michael A O'Donnell, Edward Uchio, Jason A Efstathiou, John A Taylor

Registry-linked trialOpen access · hybridAbstract readConsensus StatementReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04706598 (A Phase I/II Single Arm Study of Intravesical Administration With Camrelizumab for High-risk Non-muscle Invasive Bladder Cancer), which is not on this map. Cited by 95 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed, 4 pooled it
32.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04706598 phase1 / phase2active not recruitingnot on this mapstarted 2021, after this paper: background citation

A Phase I/II Single Arm Study of Intravesical Administration With Camrelizumab for High-risk Non-muscle Invasive Bladder Cancer(NMIBC) Failing in BCG Treatment

TypeinterventionalSponsorFudan UniversityRan2021 to 2026Enrolled25ConditionsUrinary Bladder Neoplasms, ImmunotherapyArmsCamrelizumab
3 · Its place in the literature

Who cites it

95 citing papers in PubMed, 4 syntheses or guidelines pooled it, 243 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Observational
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review of BCG immunotherapy for bladder cancer.Clinical microbiology reviews · 2025
    Review
  20. Review

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Ashish M KamatThe University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1373, Houston, TX 77030, USA.
Thomas W FlaigUniversity of Colorado, MS 8117, 12801 E. 17th Avenue, Room 8117, Aurora, CO 80045, USA.
H Barton GrossmanThe University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1373, Houston, TX 77030, USA.
Badrinath KonetyUniversity of Minnesota, 420 Delaware Street Southeast, Minneapolis, MN 55455, USA.
Donald LammBCG Oncology, 3815 East Bell Road, Suite 1210, Phoenix, AZ 85032, USA.
Michael A O'DonnellUniversity of Iowa, 200 Hawkins Drive, Iowa City, IA 52242, USA.
Edward UchioUniversity of California Irvine, 333 City Boulevard, Suite 2100, Orange, CA 92868, USA.
Jason A EfstathiouHarvard Medical School, 100 Blossom Street, Cox 3, Boston, MA 02114, USA.
John A TaylorUniversity of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030, USA.
Harvard University Press · USThe University of Texas MD Anderson Cancer Center · USUConn Health · USUniversity of California, Irvine · USUniversity of Colorado Boulder · USUniversity of Iowa · USUniversity of Minnesota · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple clinical trials have demonstrated that intravesical Bacillus Calmette-Guérin (BCG) treatment reduces recurrences and progression in patients with non-muscle-invasive bladder cancer (NMIBC). However, although BCG has been in use for almost 40 years, this agent is often underutilized and practice patterns of administration vary. This neglect is most likely caused by uncertainties about the optimal use of BCG, including unawareness of optimal treatment schedules and about patient populations that most benefit from BCG treatment. To address this deficit, a focus group of specialized urologic oncologists (urologists, medical oncologists and radiation oncologists) reviewed the current guidelines and clinical evidence, discussed their experiences and formed a consensus regarding the optimal use of BCG in the management of patients with NIMBC. The experts concluded that continuing therapy with 3-week BCG maintenance is superior to induction treatment only and is the single most important factor in improving outcomes in patients with NMIBC. They also concluded that a reliable alternative to radical cystectomy in truly BCG-refractory disease remains the subject of clinical trials. In addition, definitions for common terms of BCG failure, such as BCG-refractory and BCG-intolerant, have been formulated.

Indexed as

Administration, IntravesicalBCG VaccineBenchmarkingCombined Modality TherapyHumansImmunotherapyMaleTreatment OutcomeUrinary Bladder NeoplasmsBCG Vaccine

Identifiers

PMID25800393
OpenAlexW2084204019

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.